Cargando…
Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials
PURPOSE: The purpose of this study was to evaluate the safety and tolerability profile of drugs used for treating common eye disorders when applied to normal healthy volunteers (NHVs) as explored in phase 1 trials. SUBJECTS AND METHODS: A total of 166 NHVs were identified in six phase 1 trials, exam...
Autores principales: | Muñoz-Villegas, Patricia, Navarro-Sánchez, Andrea A, Sánchez-Ríos, Alejandra, Olvera-Montaño, Oscar, Baiza-Durán, Leopoldo M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544558/ https://www.ncbi.nlm.nih.gov/pubmed/34707360 http://dx.doi.org/10.2147/TCRM.S331294 |
Ejemplares similares
-
Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial
por: Baiza-Durán, Leopoldo M., et al.
Publicado: (2023) -
Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits
por: Baiza-Durán, Leopoldo, et al.
Publicado: (2020) -
Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate
por: Sánchez‐Ríos, Alejandra, et al.
Publicado: (2022) -
Evaluation of the Rheological Properties, Preclinical Safety, and Clinical Effectiveness of a New Dispersive Ophthalmic Viscoelastic Device for Cataract Surgery
por: Palacio-Pastrana, Claudia, et al.
Publicado: (2022) -
Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021)